PIEZO1 and escherichia coli infection: coli infection (Fig. 4g, h), the production of mROS and cellular ROS in response to LPS treatment or E. coli infection (Fig. 4i and Supplemental Fig. 4e), as well as the ability of bacterial phagocytosis and clearance (Fig. 4j) in Piezo1-deficient BMDMs.